Scoop: Med­Im­mune chief Bahi­ja Jal­lal is leav­ing As­traZeneca and join­ing the trek in­to biotech

Six years af­ter As­traZeneca’s then new CEO Pas­cal So­ri­ot named Bahi­ja Jal­lal pres­i­dent of the big Med­Im­mune sub­sidiary in Gaithers­burg, MD, putting her at the cen­ter of the com­pa­ny’s R&D turn­around plans, the long­time phar­ma ex­ec is join­ing the great mi­gra­tion of in­dus­try pro­fes­sion­als to biotech.

Eliot Forster

Jal­lal is tak­ing the helm at Im­muno­core next week, a promi­nent TCR play­er in the UK which has been go­ing through a re­mark­able shake­up af­ter the orig­i­nal team un­der CEO Eliot Forster — now chief at F-star — ei­ther left or were forced out. Im­muno­core was able to raise $320 mil­lion a lit­tle more than 3 years ago — a time when that kind of mon­ey was still able to cause as­ton­ish­ment in the in­dus­try.

This wasn’t the first such biotech job to come along, Jal­lal tells me in an ex­clu­sive in­ter­view ahead of the an­nounce­ment. “But when the right one is there you jump on it.”

The job starts on Mon­day, and Jal­lal says she feels like “a kid in a can­dy store” when it comes to Im­muno­core, a com­pa­ny with a broad plat­form that is built to ac­com­mo­date on­col­o­gy as well as in­fec­tious dis­eases and au­toim­mune con­di­tions.

And Jal­lal isn’t the on­ly se­nior As­traZeneca ex­ec head­ing to new biotech fields. The Wall Street Jour­nal re­ports to­day that Mark Mal­lon — cur­rent EVP in charge of port­fo­lio strat­e­gy — is on his way to take the CEO job at Iron­wood, as that com­pa­ny splits up un­der pres­sure and Pe­ter Hecht leaves to run the R&D spin­out.

An­drew Hotchkiss

Over the past year-plus Im­muno­core has run in­to some se­vere tur­bu­lence af­ter it tried to shop a new round at its old uni­corn val­u­a­tion. Po­ten­tial in­vestors weren’t ready to buy in, trig­ger­ing an ex­o­dus at the top and a move up for chief com­mer­cial of­fi­cer An­drew Hotchkiss as in­ter­im chief.

Jal­lal says Hotchkiss has done a great job this year, which in­cludes ink­ing a ma­jor new pact with Genen­tech, and he’ll go back to con­cen­trat­ing on his com­mer­cial fo­cus with an eye on ad­vanc­ing Im­muno­core’s late-stage can­cer ther­a­py to­ward the mar­ket.

“I can tell you there’s been a lot of progress in the past year,” she adds. “Next week we’re go­ing to JP­Mor­gan and share the sto­ry with the in­vestor com­mu­ni­ty and oth­ers. My in­ten­tion is to bring re­as­sur­ance to in­vestors that I will bring sta­bil­i­ty to the or­ga­ni­za­tion, bring the best team and have the vi­sion we can all work to­geth­er and show them why I am join­ing the com­pa­ny.”

Mene Pan­ga­los

Jal­lal was one of three top R&D ex­ecs So­ri­ot picked for the Big Phar­ma’s turn­around in 2013. Brig­gs Mor­ri­son left sev­er­al years ago to run Syn­dax. That leaves Mene Pan­ga­los and his new col­leagues to run the show at As­traZeneca’s re­search and de­vel­op­ment op­er­a­tions.

There’s no im­me­di­ate word on who will re­place Jal­lal at Med­im­mune, where she steered 5 drugs to an ap­proval, in­clud­ing their check­point play­er Imfinzi.


Im­age: Bahi­ja Jal­lal. MED­IM­MUNE

MedTech clinical trials require a unique regulatory and study design approach and so engaging a highly experienced CRO to ensure compliance and accurate data across all stages is critical to development milestones.

In­no­v­a­tive MedTech De­mands Spe­cial­ist Clin­i­cal Tri­al Reg­u­la­to­ry Af­fairs and De­sign

Avance Clinical is the Australian CRO for international biotechs providing world-class clinical research services with FDA-accepted data across all phases. With Avance Clinical, biotech companies can leverage Australia’s supportive clinical trials environment which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend. The CRO has been delivering clinical drug development services for international biotechs for FDA and EMA regulatory approval for the past 24 years. The company has been recognized for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award and a finalist in Informa Pharma’s Best CRO award for 2022.

His­toric drug pric­ing re­forms pass; Pfiz­er ac­quires GBT; The long search for non-opi­oid pain drugs; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The Endpoints Weekly has officially crossed the 60,000 mark on subscribers — thanks to all of your support. As the editorial team grows, we’ve been able to do a lot more, with many of those on display this week. Be sure to check out Lei Lei Wu’s deep dive on pain R&D. If you missed it, you may also rewatch her companion panel here.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.

Gold for adults, sil­ver for in­fants: Pfiz­er's Pre­vnar 2.0 head­ed to FDA months af­ter Mer­ck­'s green light

Pfizer was first to the finish line for the next-gen pneumococcal vaccine in adults, but Merck beat its rival with a jab for children in June.

Now, two months after Merck’s 15-valent Vaxneuvance won the FDA stamp of approval for kids, Pfizer is out with some late-stage data on its 20-valent shot for infants.

Known as Prevnar 20 for adults, Pfizer’s 20vPnC will head to the FDA by the end of this year for an approval request in infants, the Big Pharma said Friday morning. Discussions with the FDA will occur first and more late-stage pediatric trials are expected to read out soon, informing the regulatory pathway in other countries and regions.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.

Seagen interim CEO Roger Dansey and Daiichi Sankyo CEO Sunao Manabe

Paving the way for Mer­ck­'s buy­out, Seagen los­es ar­bi­tra­tion dis­pute with Dai­ichi over ADC tech

As Seagen awaits a final buyout offer from Merck that could be in the territory of $40 billion, Seagen revealed Friday afternoon that it lost an arbitration dispute with Daiichi Sankyo relating to the companies’ 2008 collaboration around the use of antibody-drug conjugate (ADC) technology.

But that loss likely won’t matter much when it comes to Merck’s deal.

After breaking off its pact with Daiichi in mid-2015, the two companies battled over “linker” tech — a chemical bridge between an ADC’s antibody component and the cytotoxic payload — that Seagen claims Daiichi would improve upon and implement in its current generation of ADCs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.

Winselow Tucker, Eli Lilly's new Loxo unit chief commercial officer

Eli Lil­ly plucks a new com­mer­cial chief from Bris­tol My­ers in man­age­ment shuf­fle as HR chief re­tires

Eli Lilly has found a new chief commercial officer from among the ranks at Bristol Myers Squibb, as it says farewell to its longtime head of human resources Stephen Fry.

Fry announced on Thursday his plans to retire after more than 35 years with Lilly. He’ll vacate his seat as SVP of human resources and diversity at the end of the year, and current Loxo CCO Eric Dozier is slated to take his place. As a result, BMS’ Winselow Tucker is joining the team as Loxo CCO at the end of the month.

Simba Gill, Evelo Biosciences CEO

Sim­ba Gill heads back to Flag­ship af­ter sev­en-year run as Evelo CEO

Evelo Biosciences is on the hunt for a new CEO, with its founding chief Simba Gill switching to the chairman post to free up time for his new gig at Evelo’s incubator, Flagship Pioneering.

Gill will trade in his former Flagship title of venture partner with the higher-up role of executive partner, after originally joining in 2015. He’ll serve as CEO of Evelo until his successor is chosen, and at Flagship his priorities will be counseling and supporting the venture firm’s portfolio companies.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.

House pass­es his­toric drug pric­ing re­forms, lin­ing up decades-in-the-mak­ing win for Biden and De­moc­rats

The US House of Representatives today voted along party lines (all Dems voted for it), 220-207 to pass new, wide-ranging legislation that will allow Medicare drug price negotiations for the first time ever, and cap seniors’ drug expenses to $2,000 per year and seniors’ insulin costs at $35 per month.

Setting up a major victory for President Joe Biden, representatives returned from their summer recess to pass the Inflation Reduction Act, even as many noted the bill would only modestly reduce inflation.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.

Senate Finance Committee Chair Ron Wyden (D-OR) (Francis Chung/E&E News/POLITICO via AP Images)

Sen­ate Fi­nance chair con­tin­ues his in­ves­ti­ga­tion in­to phar­ma tax­es with re­quests for Am­gen

Amgen is the latest pharma company to appear on the radar of Senate Finance Committee Chair Ron Wyden (D-OR), who is investigating the way pharma companies are using subsidiaries in low- or zero-tax countries to lower their tax bills.

Like its peers Merck, AbbVie and Bristol Myers Squibb, Wyden notes how Amgen uses its Puerto Rico operations to consistently pay tax rates that are substantially lower than the U.S. corporate tax rate of 21%, with an effective tax rate of 10.7% in 2020 and 12.1% in 2021.

FDA ap­proves sec­ond in­di­ca­tion for As­traZeneca and Dai­ichi's En­her­tu in less than a week

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu scored its second approval in less than a week, this time for a subset of lung cancer patients.

Enhertu received accelerated approval on Thursday to treat adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, and who have already received a prior systemic therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 147,800+ biopharma pros reading Endpoints daily — and it's free.